Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Phase I/II Study of Carfilzomib in Combination With Bendamustine and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Sponsor: Suzanne Lentzsch, MD
Terminated
Slow accrual and loss of funding
Other Multiple Myeloma trials with similar outcome
Listed as NCT02002598, this PHASE1/PHASE2 trial focuses on Multiple Myeloma and remains terminated or withdrawn. Sponsored by Suzanne Lentzsch, MD, it has been updated 11 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Oct 2024 — Present [monthly]
Terminated PHASE1/PHASE2
Status: Completed → Terminated
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
▶ Show 6 earlier versions
-
Feb 2019 — Jul 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Suzanne Lentzsch, MD
For direct contact, visit the study record on ClinicalTrials.gov .